Sai Parenterals renews ₹1,300-cr Australia OTC deal

What Sai Parenterals announced

Sai Parenterals Limited has renewed a long-term, exclusive Over-The-Counter (OTC) medicines supply agreement in Australia through Noumed Pharmaceuticals Pty Ltd, its Australian step-down subsidiary. The renewed contract is with one of Australia’s leading pharmacy networks and covers the exclusive supply of a comprehensive portfolio of OTC pharmaceutical products across the country.

The company disclosed in regulatory filings that the renewed agreement is valued at AUD 202 million, which it approximated at about ₹1,300 crore, for an initial 7.5-year term. The agreement is scheduled to be implemented from July 1, 2026.

Why two different deal values were circulating

Alongside the company’s disclosures, an input alert circulated a smaller contract value of AUD 30 million. The alert itself noted that this figure was not independently verified.

Sai Parenterals’ official disclosures to Indian exchanges (BSE and NSE) state the renewed agreement value as about ₹1,300 crore for the initial tenure. For investors, the key takeaway is that the company’s filings place the agreement at a significantly larger value than what was mentioned in the alert.

Tenure, extension option, and start date

As per the exchange filing, the renewed agreement takes effect from July 1, 2026 and remains valid for 7.5 years. The contract also includes an option to extend the arrangement by an additional three years, subject to mutual consent.

That structure gives Noumed a long operating runway with a large retail pharmacy customer in a regulated market. The extension clause is not automatic, but it provides a defined framework for a longer relationship if both parties agree later.

Revenue visibility and implied annual run-rate

Based on the company’s disclosure, the agreement works out to an average annual business of about AUD 27 million, which the disclosure context translates to around ₹174 crore per annum. The company positioned the contract as providing long-term revenue visibility for the Australian business.

The agreement was also described as supporting steady cash flows for at least the 7.5-year initial term starting July 1, 2026. The company commentary characterised these cash flows as high-margin, tied to an exclusive supply arrangement.

Product pipeline: 12 launches a year

A notable operational element of the renewed agreement is a development pipeline aimed at expanding the product portfolio. The contract targets the launch of 12 new products every year during the tenure.

The company indicated that this steady addition of products is intended to expand the scope of the portfolio supplied under the agreement and, over time, lift the overall contract value. The disclosures frame the renewal as an expansion in portfolio and agreement value compared with the earlier arrangement.

What Noumed will handle under the agreement

Sai Parenterals said Noumed will continue as an exclusive supplier of OTC pharmaceutical products in the Australian market. Under the agreement, Noumed’s responsibilities include:

• manufacturing and product sourcing
• regulatory compliance
• TGA registrations
• warehousing
• quality assurance
• nationwide distribution

These responsibilities matter because they indicate Noumed is positioned as an end-to-end partner rather than a narrow supplier, covering compliance-heavy functions in Australia’s regulated environment.

Corporate context: Sai Parenterals’ Noumed acquisition

Sai Parenterals acquired a 74.64% majority stake in Adelaide-based Noumed Pharmaceuticals Pty Ltd in November 2025 for ₹125 crore. The renewed multi-year supply agreement strengthens the commercial foundation of that acquisition and links Noumed’s operating outlook to a long-duration retail-pharmacy channel relationship.

The company also clarified in its filing that the contract is awarded by an international customer and is not a related-party transaction. It further stated that neither promoters nor promoter group entities have any interest in the awarding organisation.

Stock market reaction on the announcement day

The announcement triggered an immediate reaction in the stock price. As of 9:19 AM IST on July 2, shares of Sai Parenterals were trading at ₹652.95, up 6.67% in early trade.

While short-term price moves can reflect many factors, the market response on the day highlighted investor focus on the size of the disclosed contract and the visibility implied by a 7.5-year term.

Key disclosed numbers at a glance

Why the renewal matters for Sai Parenterals’ Australia strategy

The renewed agreement combines three elements that are closely tracked in overseas expansion stories: long-term contracted visibility, operational responsibility across compliance and distribution, and a product pipeline meant to broaden the portfolio over time.

With an exclusive supply arrangement running for 7.5 years and a possible three-year extension, the deal sets a clear demand channel for Noumed in Australia. It also places execution emphasis on maintaining regulatory compliance, managing registrations, and reliably supporting nationwide distribution, as outlined in the company’s disclosures.

Conclusion

Sai Parenterals’ renewed Noumed-led OTC supply agreement, disclosed at about ₹1,300 crore for 7.5 years starting July 1, 2026, provides a defined revenue runway and a structured plan to expand the product portfolio through 12 new launches annually. The next key milestone to track is the contract’s implementation from the July 2026 start date and any future update on the optional three-year extension, if pursued by both parties.